Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAMI M ALI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1821382250
CMS profile
1379339
Location
SNELLVILLE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$7,080.90

278 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $5,815.43 269
Consulting Fee $655.50 1
Education $359.98 5
Long term medical supply or device loan $249.99 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Bayer Healthcare Pharmaceuticals Inc. $790.09 9
Teva Pharmaceuticals USA, Inc. $746.38 60
NOVARTIS PHARMACEUTICALS CORPORATION $745.34 24
Exelixis Inc. $359.51 5
Janssen Biotech, Inc. $318.99 12
AstraZeneca Pharmaceuticals LP $280.17 9
E.R. Squibb & Sons, L.L.C. $278.67 12
PFIZER INC. $278.60 16
Seagen Inc. $266.08 8
Incyte Corporation $240.39 8
GlaxoSmithKline, LLC. $235.64 6
Merck Sharp & Dohme LLC $188.68 8
Astellas Pharma US Inc $171.17 7
Daiichi Sankyo Inc. $154.27 6
Amgen Inc. $153.52 9
Takeda Pharmaceuticals U.S.A., Inc. $152.34 6
Eisai Inc. $140.41 9
Celgene Corporation $130.14 6
Karyopharm Therapeutics Inc. $112.07 4
GENZYME CORPORATION $103.87 4
Lilly USA, LLC $100.22 4
Pharmacyclics LLC, An AbbVie Company $99.63 4
Regeneron Healthcare Solutions, Inc. $94.77 3
Blueprint Medicines Corporation $78.54 3
ImmunoGen, Inc. $75.09 3
Mirati Therapeutics, Inc. $64.72 3
PharmaEssentia USA Corporation $59.69 2
AbbVie Inc. $56.03 2
EMD Serono, Inc. $52.87 2
Agios Pharmaceuticals, Inc. $43.79 2
MorphoSys, US Inc. $42.79 2
Progenics Pharmaceuticals, Inc. $30.77 1
Puma Biotechnology, Inc. $29.92 1
Jazz Pharmaceuticals Inc. $28.19 1
TAIHO ONCOLOGY, INC. $27.94 1
Amneal Pharmaceuticals LLC $27.89 1
Stemline Therapeutics Inc. $27.00 1
Foundation Medicine, Inc. $26.89 1
Catalyst Pharmaceuticals, Inc. $26.23 1
Novocure Inc. $25.69 1
Tolmar, Inc. $24.27 1
Boehringer Ingelheim Pharmaceuticals, Inc. $23.35 1
Genentech USA, Inc. $22.87 1
Gilead Sciences, Inc. $22.52 1
Rigel Pharmaceuticals, Inc. $19.82 1
Boston Scientific Corporation $18.95 1
AVEO Pharmaceuticals, Inc. $18.63 1
G1 Therapeutics, Inc. $18.40 1
Secura Bio, Inc. $17.32 1
Kite Pharma, Inc. $15.96 1
SOBI, INC $13.82 1

Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAMI M ALI

NPI 1821382250 · CMS profile ID 1379339

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SNELLVILLE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821382250?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAMI M ALI, NPI 1821382250, CMS profile ID 1379339. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821382250?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SAMI M ALI, NPI 1821382250, CMS profile ID 1379339. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821382250?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SAMI M ALI, NPI 1821382250, CMS profile ID 1379339, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1821382250?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

278 matching records · $7,080.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 278 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 278.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $32.6310/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050275481 CMS
Eisai Inc. $5.7210/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023331137 CMS
Teva Pharmaceuticals USA, Inc. $13.7910/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056797251 CMS
Amneal Pharmaceuticals LLC $27.8910/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053473015 CMS
PFIZER INC. $25.0010/18/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049547481 CMS
PFIZER INC. $21.0710/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050556735 CMS
Eisai Inc. $6.0110/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023331133 CMS
ImmunoGen, Inc. $22.9010/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017252309 CMS
Bayer Healthcare Pharmaceuticals Inc. $1.9010/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000498426 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.4510/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000518769 CMS
Agios Pharmaceuticals, Inc. $22.3210/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056205977 CMS
Teva Pharmaceuticals USA, Inc. $20.7910/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056797249 CMS
Amgen Inc. $16.0510/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020107885 CMS
Seagen Inc. $98.0010/12/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995755425 CMS
E.R. Squibb & Sons, L.L.C. $29.0110/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015693181 CMS
GlaxoSmithKline, LLC. $20.1210/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002716535 CMS
TAIHO ONCOLOGY, INC. $27.9410/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055235685 CMS
Teva Pharmaceuticals USA, Inc. $20.3410/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056797253 CMS
Teva Pharmaceuticals USA, Inc. $18.3209/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056797247 CMS
Bayer Healthcare Pharmaceuticals Inc. $655.5009/26/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000531053 CMS
Eisai Inc. $19.4709/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023331135 CMS
Teva Pharmaceuticals USA, Inc. $14.8809/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056797243 CMS
Amgen Inc. $26.1609/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020107881 CMS
Pharmacyclics LLC, An AbbVie Company $24.4009/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998280971 CMS
Merck Sharp & Dohme LLC $14.7009/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048752809 CMS
E.R. Squibb & Sons, L.L.C. $22.5609/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015693163 CMS
Incyte Corporation $83.9909/18/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044613347 CMS
Teva Pharmaceuticals USA, Inc. $14.3709/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056797239 CMS
Bayer Healthcare Pharmaceuticals Inc. $7.8209/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000498847 CMS
Exelixis Inc. $32.4309/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044598701 CMS
Bayer Healthcare Pharmaceuticals Inc. $28.8409/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000526263 CMS
Catalyst Pharmaceuticals, Inc. $26.2309/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048229175 CMS
Seagen Inc. $28.8709/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995755177 CMS
Teva Pharmaceuticals USA, Inc. $12.5809/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056797241 CMS
Blueprint Medicines Corporation $25.7609/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051259073 CMS
PFIZER INC. $14.0609/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050705659 CMS
EMD Serono, Inc. $34.4709/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032321453 CMS
Pharmacyclics LLC, An AbbVie Company $19.4509/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998280969 CMS
AstraZeneca Pharmaceuticals LP $23.5108/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015022749 CMS
Teva Pharmaceuticals USA, Inc. $16.8408/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056797235 CMS
Incyte Corporation $29.4708/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044613221 CMS
PharmaEssentia USA Corporation $32.5108/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059299571 CMS
Regeneron Healthcare Solutions, Inc. $35.5608/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999073739 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.9708/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055330661 CMS
Merck Sharp & Dohme LLC $24.9508/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048376727 CMS
Lilly USA, LLC $26.0208/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032383919 CMS
Mirati Therapeutics, Inc. $21.3008/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057985127 CMS
PFIZER INC. $4.7108/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049458561 CMS
PFIZER INC. $26.3608/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049434805 CMS
Exelixis Inc. $27.4108/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044590671 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,626.29 137
PY2020 $2,665.36 122
PY2021 $5,087.77 226
PY2022 $5,248.34 232
PY2023 $7,080.90 278
PY2024 $6,496.30 256
PY2025 $4,646.67 164

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $590,171.10 178
PY2024 Principal investigator $191,916.13 66
PY2023 Principal investigator $39,142.42 16
PY2022 Principal investigator $115,679.07 13
PY2021 Recipient $250.00 1
PY2021 Principal investigator $166,418.59 35
PY2020 Principal investigator $91,724.32 9
PY2019 Principal investigator $199,763.40 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

178 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $61.00 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167699
Principal investigator 1 Janssen Research & Development, LLC $600.00 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167776
Principal investigator 1 Janssen Research & Development, LLC $9,381.00 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167787
Principal investigator 1 Janssen Research & Development, LLC $728.10 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168079
Principal investigator 1 Janssen Research & Development, LLC $14,835.00 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168183
Principal investigator 1 Janssen Research & Development, LLC $8,875.00 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168361
Principal investigator 1 Janssen Research & Development, LLC $74.74 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168406
Principal investigator 1 Janssen Research & Development, LLC $600.00 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168451
Principal investigator 1 Janssen Research & Development, LLC $62.64 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168457
Principal investigator 1 Janssen Research & Development, LLC $1,176.30 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168483
Principal investigator 1 Janssen Research & Development, LLC $809.00 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168491
Principal investigator 1 Janssen Research & Development, LLC $54.90 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168799
Principal investigator 1 Janssen Research & Development, LLC $728.10 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168822
Principal investigator 1 Janssen Research & Development, LLC $59,784.30 12/24/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168830
Principal investigator 1 Merck Sharp & Dohme LLC $84,864.00 12/22/2025 Non-covered Recipient Entity
The Oncology Institute of Hope and Innovation
A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1232935719
Principal investigator 1 Janssen Research & Development, LLC $137.84 12/05/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167756
Principal investigator 1 Janssen Research & Development, LLC $104.88 12/05/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167802
Principal investigator 1 Janssen Research & Development, LLC $148.90 12/05/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167840
Principal investigator 1 Janssen Research & Development, LLC $27.90 12/05/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168166
Principal investigator 1 Janssen Research & Development, LLC $72.57 12/05/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168208
Principal investigator 1 Janssen Research & Development, LLC $75.88 12/05/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168231
Principal investigator 1 Janssen Research & Development, LLC $74.46 12/05/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168894
Principal investigator 1 Janssen Research & Development, LLC $809.00 11/26/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168223
Principal investigator 1 Janssen Research & Development, LLC $600.00 11/26/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168247
Principal investigator 1 Janssen Research & Development, LLC $809.00 11/26/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168443
Principal investigator 1 Janssen Research & Development, LLC $809.00 10/15/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167769
Principal investigator 1 Janssen Research & Development, LLC $72.68 10/15/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167879
Principal investigator 1 Janssen Research & Development, LLC $809.00 10/15/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168534
Principal investigator 1 Janssen Research & Development, LLC $450.00 10/15/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168593
Principal investigator 1 Janssen Research & Development, LLC $18,056.00 10/15/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168757
Principal investigator 1 Janssen Research & Development, LLC $32.99 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167712
Principal investigator 1 Janssen Research & Development, LLC $728.10 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167740
Principal investigator 1 Janssen Research & Development, LLC $42.64 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167748
Principal investigator 1 Janssen Research & Development, LLC $77.40 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167763
Principal investigator 1 Janssen Research & Development, LLC $614.00 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167809
Principal investigator 1 Janssen Research & Development, LLC $31.98 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167827
Principal investigator 1 Janssen Research & Development, LLC $250.00 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167872
Principal investigator 1 Janssen Research & Development, LLC $56.13 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167885
Principal investigator 1 Janssen Research & Development, LLC $52.97 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167894
Principal investigator 1 Janssen Research & Development, LLC $47.80 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167911
Principal investigator 1 Janssen Research & Development, LLC $614.00 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167918
Principal investigator 1 Janssen Research & Development, LLC $13,351.50 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167926
Principal investigator 1 Janssen Research & Development, LLC $450.00 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167935
Principal investigator 1 Janssen Research & Development, LLC $53.02 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167943
Principal investigator 1 Janssen Research & Development, LLC $50.27 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167973
Principal investigator 1 Janssen Research & Development, LLC $450.00 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168011
Principal investigator 1 Janssen Research & Development, LLC $614.00 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168062
Principal investigator 1 Janssen Research & Development, LLC $614.00 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168070
Principal investigator 1 Janssen Research & Development, LLC $350.00 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168087
Principal investigator 1 Janssen Research & Development, LLC $14.99 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168117
Principal investigator 1 Janssen Research & Development, LLC $292.50 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168215
Principal investigator 1 Janssen Research & Development, LLC $27.99 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168239
Principal investigator 1 Janssen Research & Development, LLC $54.37 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168255
Principal investigator 1 Janssen Research & Development, LLC $728.10 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168327
Principal investigator 1 Janssen Research & Development, LLC $29.90 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168346
Principal investigator 1 Janssen Research & Development, LLC $51.70 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168352
Principal investigator 1 Janssen Research & Development, LLC $728.10 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168412
Principal investigator 1 Janssen Research & Development, LLC $25.86 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168578
Principal investigator 1 Janssen Research & Development, LLC $1,370.00 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168586
Principal investigator 1 Janssen Research & Development, LLC $63.00 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168733
Principal investigator 1 Janssen Research & Development, LLC $51.68 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168748
Principal investigator 1 Janssen Research & Development, LLC $604.80 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168782
Principal investigator 1 Janssen Research & Development, LLC $51.70 10/10/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168901
Principal investigator 1 Janssen Research & Development, LLC $126.89 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167727
Principal investigator 1 Janssen Research & Development, LLC $7,647.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167795
Principal investigator 1 Janssen Research & Development, LLC $127.93 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167817
Principal investigator 1 Janssen Research & Development, LLC $338.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167862
Principal investigator 1 Janssen Research & Development, LLC $141.88 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167902
Principal investigator 1 Janssen Research & Development, LLC $8,747.10 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167979
Principal investigator 1 Janssen Research & Development, LLC $809.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167989
Principal investigator 1 Janssen Research & Development, LLC $809.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168022
Principal investigator 1 Janssen Research & Development, LLC $7,747.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168031
Principal investigator 1 Janssen Research & Development, LLC $7,511.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168045
Principal investigator 1 Janssen Research & Development, LLC $325.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168093
Principal investigator 1 Janssen Research & Development, LLC $614.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168109
Principal investigator 1 Janssen Research & Development, LLC $250.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168126
Principal investigator 1 Janssen Research & Development, LLC $68.92 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168135
Principal investigator 1 Janssen Research & Development, LLC $74.98 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168174
Principal investigator 1 Janssen Research & Development, LLC $119.56 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168191
Principal investigator 1 Janssen Research & Development, LLC $80.19 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168296
Principal investigator 1 Janssen Research & Development, LLC $69.26 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168304
Principal investigator 1 Janssen Research & Development, LLC $714.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168337
Principal investigator 1 Janssen Research & Development, LLC $10,096.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168367
Principal investigator 1 Janssen Research & Development, LLC $82.95 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168390
Principal investigator 1 Janssen Research & Development, LLC $809.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168398
Principal investigator 1 Janssen Research & Development, LLC $18,056.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168420
Principal investigator 1 Janssen Research & Development, LLC $195.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168466
Principal investigator 1 Janssen Research & Development, LLC $809.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168473
Principal investigator 1 Janssen Research & Development, LLC $338.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168501
Principal investigator 1 Janssen Research & Development, LLC $18,056.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168561
Principal investigator 1 Janssen Research & Development, LLC $614.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168603
Principal investigator 1 Janssen Research & Development, LLC $809.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168610
Principal investigator 1 Janssen Research & Development, LLC $163.90 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168619
Principal investigator 1 Janssen Research & Development, LLC $614.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168637
Principal investigator 1 Janssen Research & Development, LLC $250.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168671
Principal investigator 1 Janssen Research & Development, LLC $18,056.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168701
Principal investigator 1 Janssen Research & Development, LLC $250.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168708
Principal investigator 1 Janssen Research & Development, LLC $7,747.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168766
Principal investigator 1 Janssen Research & Development, LLC $68.46 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168790
Principal investigator 1 Janssen Research & Development, LLC $600.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168864
Principal investigator 1 Janssen Research & Development, LLC $795.00 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168871
Principal investigator 1 Janssen Research & Development, LLC $65.85 10/08/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168885
Principal investigator 1 BioNTech SE $269.10 09/23/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
BNT-122-01 No dispute reported 06/30/2026 1249016026
Principal investigator 1 BioNTech SE $80.60 09/23/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
BNT-122-01 No dispute reported 06/30/2026 1249016210
Principal investigator 1 AstraZeneca UK Limited $17,704.50 09/10/2025 Non-covered Recipient Entity
HELIOS CLINICAL RESEARCH
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185544839
Principal investigator 1 Janssen Research & Development, LLC $256.00 08/25/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175427570
Principal investigator 1 BioNTech SE $500.00 07/31/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
BNT-122-01 No dispute reported 06/30/2026 1249016028
Principal investigator 1 BioNTech SE $1,500.00 07/31/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
BNT-122-01 No dispute reported 06/30/2026 1249016208
Principal investigator 1 Janssen Research & Development, LLC $1,430.10 07/09/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168428
Principal investigator 1 Janssen Research & Development, LLC $256.00 07/07/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175427554
Principal investigator 1 Janssen Research & Development, LLC $5,921.00 07/07/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175427613
Principal investigator 1 Janssen Research & Development, LLC $256.00 07/07/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175427751
Principal investigator 1 Janssen Research & Development, LLC $728.10 06/04/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168279
Principal investigator 1 Janssen Research & Development, LLC $728.10 06/04/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168384
Principal investigator 1 Janssen Research & Development, LLC $728.10 06/04/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168662
Principal investigator 1 Janssen Research & Development, LLC $728.10 06/04/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168807
Principal investigator 1 Janssen Research & Development, LLC $104.49 06/03/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175369211
Principal investigator 1 Janssen Research & Development, LLC $3,434.00 06/02/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175369081
Principal investigator 1 BioNTech SE $250.00 05/22/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
BNT-122-01 No dispute reported 06/30/2026 1249016144
Principal investigator 1 BioNTech SE $250.00 05/22/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
BNT-122-01 No dispute reported 06/30/2026 1249016146
Principal investigator 1 BioNTech SE $250.00 05/22/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
BNT-122-01 No dispute reported 06/30/2026 1249016148
Principal investigator 1 BioNTech SE $250.00 05/22/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
BNT-122-01 No dispute reported 06/30/2026 1249016150
Principal investigator 1 BioNTech SE $250.00 05/22/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
BNT-122-01 No dispute reported 06/30/2026 1249016152
Principal investigator 1 BioNTech SE $250.00 05/22/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
BNT-122-01 No dispute reported 06/30/2026 1249016206
Principal investigator 1 ABBVIE INC. $2,500.00 05/07/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1202482917
Principal investigator 1 Janssen Research & Development, LLC $80.02 05/07/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168003
Principal investigator 1 Janssen Research & Development, LLC $80.55 05/07/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168654
Principal investigator 1 Janssen Research & Development, LLC $4,438.80 05/07/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168690
Principal investigator 1 Janssen Research & Development, LLC $83.47 04/30/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168101
Principal investigator 1 Janssen Research & Development, LLC $92.75 04/22/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175369188
Principal investigator 1 Janssen Research & Development, LLC $3,434.00 04/21/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175369136
Principal investigator 1 Janssen Research & Development, LLC $3,434.00 04/21/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175369166
Principal investigator 1 Janssen Research & Development, LLC $3,434.00 04/21/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175369180
Principal investigator 1 Janssen Research & Development, LLC $11,039.40 04/18/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167856
Principal investigator 1 Janssen Research & Development, LLC $11,039.40 04/18/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167998
Principal investigator 1 Janssen Research & Development, LLC $780.00 04/16/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167734
Principal investigator 1 Janssen Research & Development, LLC $540.00 04/16/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167951
Principal investigator 1 Janssen Research & Development, LLC $2,542.50 04/16/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168198
Principal investigator 1 Janssen Research & Development, LLC $4,429.80 04/16/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168263
Principal investigator 1 Janssen Research & Development, LLC $77.38 04/16/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168376
Principal investigator 1 Janssen Research & Development, LLC $76.73 04/16/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168435
Principal investigator 1 Janssen Research & Development, LLC $74.84 04/16/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168570
Principal investigator 1 Janssen Research & Development, LLC $1,055.70 04/16/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168839
Principal investigator 1 Janssen Research & Development, LLC $540.00 04/16/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168848
Principal investigator 1 Janssen Research & Development, LLC $73.81 04/11/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167964
Principal investigator 1 Janssen Research & Development, LLC $19,005.30 04/11/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168143
Principal investigator 1 Janssen Research & Development, LLC $67.86 04/11/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168681
Principal investigator 1 Janssen Research & Development, LLC $702.00 04/11/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168774
Principal investigator 1 Janssen Research & Development, LLC $500.00 04/11/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175368971
Principal investigator 1 Janssen Research & Development, LLC $116.94 04/11/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175368995
Principal investigator 1 Amgen Inc. $17,350.00 04/01/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1246649811
Principal investigator 1 Janssen Research & Development, LLC $50.00 03/12/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168645
Principal investigator 1 Janssen Research & Development, LLC $7,554.60 03/07/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168270
Principal investigator 1 AstraZeneca UK Limited $9,399.00 03/05/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185544841
Principal investigator 1 Merck Sharp & Dohme LLC $10,608.00 03/04/2025 Non-covered Recipient Entity
The Oncology Institute of Hope and Innovation
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2,3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma No dispute reported 06/30/2026 1232935629
Principal investigator 1 Janssen Research & Development, LLC $9,086.40 02/28/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168288
Principal investigator 1 Janssen Research & Development, LLC $69.23 02/26/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167718
Principal investigator 1 Janssen Research & Development, LLC $70.54 02/26/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168151
Principal investigator 1 Janssen Research & Development, LLC $455.00 02/26/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168509
Principal investigator 1 BioNTech SE $1,500.00 02/25/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
BNT000-001 No dispute reported 06/30/2026 1249016142
Principal investigator 1 BioNTech SE $1,500.00 02/25/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
BNT000-001 No dispute reported 06/30/2026 1249016204
Principal investigator 1 Janssen Research & Development, LLC $50,340.00 02/24/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175369066
Principal investigator 1 Janssen Research & Development, LLC $50.00 02/12/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167707
Principal investigator 1 Janssen Research & Development, LLC $4,654.80 02/12/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168039
Principal investigator 1 Janssen Research & Development, LLC $8,647.20 02/12/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168518
Principal investigator 1 Janssen Research & Development, LLC $45.24 02/12/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168629
Principal investigator 1 Janssen Research & Development, LLC $6,882.30 01/31/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168158
Principal investigator 1 Janssen Research & Development, LLC $315.00 01/31/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168814
Principal investigator 1 Janssen Research & Development, LLC $540.00 01/31/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168853
Principal investigator 1 Janssen Research & Development, LLC $50.00 01/14/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168312
Principal investigator 1 Janssen Research & Development, LLC $315.00 01/14/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168320
Principal investigator 1 Janssen Research & Development, LLC $2,260.80 01/14/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168553
Principal investigator 1 Janssen Research & Development, LLC $50.00 01/13/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167849
Principal investigator 1 Janssen Research & Development, LLC $50.00 01/13/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168052
Principal investigator 1 Janssen Research & Development, LLC $50.00 01/13/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168526
Principal investigator 1 Janssen Research & Development, LLC $2,260.80 01/13/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168545
Principal investigator 1 Janssen Research & Development, LLC $6,541.20 01/13/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168715
Principal investigator 1 Janssen Research & Development, LLC $50.00 01/13/2025 Non-covered Recipient Entity
Toi Clinic Rsrch
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175168725